Compare Biogen Inc (BIIB) vs iShares MSCI South Korea ETF (EWY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs iShares MSCI South Korea ETF — how do they compare? Biogen Inc trades at $193.38 (market cap $28.34B), while iShares MSCI South Korea ETF trades at $169.27. Which is the better fit depends on your goals.
| BIIB | EWY | |
|---|---|---|
Market Cap | $28.34B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $216.63 | $219.20 |
52-Week Low | $122.68 | $70.65 |
Enterprise Value | $30.62B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
EWY, the iShares MSCI South Korea ETF, trades at $168.08, down 8.41% over 24 hours amid a bearish technical signal. The ETF is heavily concentrated in Samsung and SK Hynix, exposing it to volatility in AI-driven semiconductor demand. Recent news highlights South Korean market turbulence, with the Kospi Index experiencing sharp declines and recoveries tied to chip stock performance. Key support lies at $162, with resistance at $171. Financial ratios are unavailable in the provided data, limiting fundamental clarity.
The outlook for EWY hinges on semiconductor cycle dynamics and foreign investor sentiment. Opportunities exist if AI memory demand rebounds, but risks include high concentration in two stocks, global tech volatility, and macroeconomic pressures. The bearish technical trend and neutral oscillators suggest cautious near-term momentum, requiring monitoring of earnings from top holdings for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →
